Title: Impaired antibacterial immune signaling and changes in the lung microbiome

precede secondary bacterial pneumonia in COVID-19

One sentence summary:

COVID-19 patients with secondary bacterial pneumonia have impaired immune signaling and

lung microbiome changes weeks before onset.

Authors:

[†]Alexandra Tsitsiklis[1], [†]Beth Shoshana Zha[2], [†]Ashley Byrne[3], [†]Catherine Devoe[1], [#]Sophia Levan[4],

[#]Elze Rackaityte[5], Sara Sunshine[5], Eran Mick[1,2,3], Rajani Ghale[1,2], Alejandra Jauregui[2], Aartik

Sarma[2], Norma Neff[3], Paula Hayakawa Serpa[1], Thomas J. Deiss[2], Amy Kistler[3], Sidney Carrillo[2],

K. Mark Ansel[6,7], Aleksandra Leligdowicz[2], Stephanie Christenson[2], Norman Jones[8], Bing Wu[9],

Spyros Darmanis[9], Michael A. Matthay[2], Susan V. Lynch[10,11], Joseph L. DeRisi[3,5], COMET

Consortium+, Carolyn M. Hendrickson[2], Kirsten N. Kangelaris[4], Matthew F. Krummel[12], Prescott

G. Woodruff[2,7], David J. Erle[4,13,14], Oren Rosenberg[1], Carolyn S. Calfee[2], *Charles R. Langelier[1,3]

[†][#]equal contributions

Affiliations:

[1]Department of Medicine, Division of Infectious Diseases, University of California San Francisco,

San Francisco, CA, USA

[2]Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine,

University of California San Francisco, San Francisco, CA, USA

[3]Chan Zuckerberg Biohub, San Francisco, CA, USA

[4]Department of Medicine, University of California San Francisco, San Francisco, CA, USA

[5]Department of Biochemistry and Biophysics, University of California San Francisco, San

Francisco, CA, USA

[6] Department of Microbiology and Immunology, University of California, San Francisco, CA, USA

[7] Sandler Asthma Basic Research Center, University of California, San Francisco, CA, USA

[8] Department of Experimental Medicine, University of California, San Francisco, CA, USA

[9] Genentech, Inc. San Francisco, CA, USA.

[10] Department of Gastroenterology, University of California, San Francisco, CA, USA

[11] Benioff Center for Microbiome Medicine, University of California, San Francisco, CA, USA

[12] Department of Pathology, University of California, San Francisco, CA, USA

[13] Lung Biology Center, University of California, San Francisco, CA, USA

[14] UCSF CoLabs, University of California, San Francisco, CA, USA

[+]COMET (COVID-19 Multiphenotyping for Effective Therapies) Consortium members are listed

in the Supplementary Appendix.

*Corresponding author

Email: chaz.langelier@ucsf.edu

Abstract

Secondary bacterial infections, including ventilator-associated pneumonia (VAP), lead to

worse clinical outcomes and increased mortality following viral respiratory infections. Critically ill

patients with coronavirus disease 2019 (COVID-19) face an elevated risk of VAP, although

susceptibility varies widely. Because mechanisms underlying VAP predisposition remained

unknown, we assessed lower respiratory tract host immune responses and microbiome dynamics

in 36 patients, including 28 COVID-19 patients, 15 of whom developed VAP, and eight critically ill

controls. We employed a combination of tracheal aspirate bulk and single cell RNA sequencing

(scRNA-seq). Two days before VAP onset, a lower respiratory transcriptional signature of

bacterial infection was observed, characterized by increased expression of neutrophil

degranulation, toll-like receptor and cytokine signaling pathways. When assessed at an earlier

time point following endotracheal intubation, more than two weeks prior to VAP onset, we

observed a striking early impairment in antibacterial innate and adaptive immune signaling that

markedly differed from COVID-19 patients who did not develop VAP. scRNA-seq further

demonstrated suppressed immune signaling across monocytes/macrophages, neutrophils and T

cells. While viral load did not differ at an early post-intubation timepoint, impaired SARS-CoV-2

clearance and persistent interferon signaling characterized the patients who later developed VAP.

Longitudinal metatranscriptomic analysis revealed disruption of lung microbiome community

composition in patients who developed VAP, providing a connection between dysregulated

immune signaling and outgrowth of opportunistic pathogens. Together, these findings

demonstrate that COVID-19 patients who develop VAP have impaired antibacterial immune

defense weeks before secondary infection onset.

Introduction

Secondary bacterial pneumonia results in significant morbidity and mortality in patients with viral lower respiratory tract infections (LRTI)*(1)*. This problem was evident in the 1918 influenza pandemic during which the majority of deaths were ultimately attributed to secondary bacterial pneumonia*(2)*. SARS-CoV-2 infection, like influenza, confers an increased risk of late onset secondary bacterial infection, often manifesting as ventilator-associated pneumonia (VAP)*(3)*. Marked heterogeneity exists with respect to the risk of VAP in patients with coronavirus disease 2019 (COVID-19), with incidence ranging from 12-87% between published cohort studies*(4–7)*.

The mechanisms underlying VAP susceptibility in COVID-19 remain unknown, and no biomarkers yet exist to inform risk of VAP at the time of intubation. Animal models of influenza may provide some insight, suggesting a role for interferon-mediated suppression of cytokines essential for bacterial defense, including neutrophil recruitment, antimicrobial peptide production and the Th17 response*(8–10)*. Few human immunoprofiling studies have been conducted in VAP however, and none have been reported in a prospective cohort of COVID-19 patients.

Lower respiratory infections represent a dynamic relationship between pathogen, host response and the lung microbiome*(11)*. Despite their interconnected roles, no studies to date have simultaneously profiled host immune responses and lung microbiome dynamics in the context of VAP. For instance, while prior work has described lung microbiome disruption in patients with VAP*(11, 12)*, the question of whether host immune responses following viral infection may contribute to this dysbiosis, leading to subsequent infection, remains unanswered.

Given the marked heterogeneity in VAP incidence among patients with COVID-19*(4–7)*, as well as gaps in mechanistic understanding of secondary bacterial pneumonia, we sought to assess the molecular determinants of VAP in the setting of SARS-CoV-2 infection. We employed a systems biology approach involving immunoprofiling the host transcriptional response and simultaneously assessing lung microbiome dynamics, using a combination of bulk and single cell

RNA sequencing and extensive clinical phenotyping. We observed a striking impairment in

antibacterial immune signaling at the time of intubation, that correlated with disruption of the lung

microbiome, weeks before the onset of VAP.

Results

We conducted a prospective case-control study of adults requiring mechanical ventilation

for COVID-19 or for illnesses other than pneumonia. Of 84 patients with COVID-19 initially

enrolled, tracheal aspirate (TA) specimens from 28 patients met inclusion criteria for analysis

(**Methods, Figure 1)**. In addition, eight critically ill patients from a second cohort (Study 2,

Methods) were included as controls. Patients were enrolled at one tertiary care hospital and one

safety net hospital in San Francisco, California under research protocols approved by the

University of California San Francisco Institutional Review Board **(Methods)**. We collected TA

periodically following intubation and performed bulk and scRNA-seq **(Methods)**.

Patients with VAP were adjudicated using the United States Centers for Disease Control

(CDC) definition*(13)*, including a requirement for a positive bacterial TA culture (N=10). Patients

who met CDC VAP criteria but had negative bacterial TA cultures were only included in a

secondary analysis (N=5). We defined onset of VAP as the first day a patient developed any of

the criteria used to meet the definition, in accordance with CDC guidance. Patients who did not

meet the CDC-NHSN criteria for VAP, and for whom there was no sustained clinical suspicion for

bacterial pneumonia during the admission, were adjudicated as No-VAP (N=13).

We compared lower respiratory tract host transcriptional responses between the VAP and

No-VAP groups at two time points. "Early" time point TA samples were collected a median of two

days post-intubation and 17 days before VAP onset (bulk RNA-seq analysis) or nine days before

VAP onset (scRNA-seq). "Late" time point samples were collected a median of two days before

VAP onset for both bulk and scRNA-seq analyses and compared against samples collected from

No-VAP patients at similar timepoints post-intubation (**Figure 1, Table S1, Table S2**). We

additionally evaluated eight intubated patients with non-pneumonia illnesses as controls at the

"early" time-point. There were no significant differences between groups with respect to age,

gender, race or ethnicity **(Table S1, S2)**. In addition, there were no differences between groups

with respect to in-hospital receipt of any immunosuppressant or antibiotics prior to sample

collection (**Table S3**).

COVID-19 VAP is associated with a transcriptional signature of bacterial infection two days

before VAP onset

We began by assessing the lower respiratory host transcriptional response two days

preceding VAP onset in COVID-19 patients. Differential gene expression analysis was carried out

on TA bulk RNA-seq data from five patients who developed VAP (samples collected a median of

two days before VAP onset) and eight patients who did not develop VAP collected within a similar

time frame after intubation **(Table S1)**. We identified 436 differentially expressed genes at a False

Discovery Rate (FDR) < 0.1 **(Figure 2A)** and performed gene set enrichment analysis (GSEA)

(Figure 2B). The patients who developed VAP exhibited upregulation of pathways related to anti-

bacterial immune responses, such as neutrophil degranulation, toll-like receptor signaling,

cytokine signaling, and antigen presentation **(Figure 2B)**. Interferon alpha/beta signaling was the

most upregulated pathway, suggesting prolonged viral infection in patients with VAP. Ingenuity

pathway analysis (IPA) additionally predicted broad activation of upstream inflammatory cytokines

in patients who developed VAP, in particular IFNα and IFNγ **(Figure 2C)**.

COVID-19 patients who develop VAP have attenuated immune signaling two weeks before

VAP onset

Given our findings of a unique lower respiratory host transcriptional signature in the 48

hours preceding VAP onset, we next asked whether differences in host immune signaling might

exist even earlier, two or more weeks before clinical diagnosis of VAP, and whether such

differences might explain the increased susceptibility to secondary bacterial infection in these

patients. We thus compared TA gene expression soon after the time of intubation between

patients who eventually developed VAP (samples collected a median of two days post-intubation,

17 days before VAP onset, n= 4) and patients who did not develop VAP (samples collected a

median of two days after intubation, n = 8) **(Table 1)**. We identified 154 differentially expressed

genes at FDR <0.1. The COVID-19 patients who developed VAP had lower expression of several

genes with roles in innate immunity including *IFI30, MMP2, TLR9*, and *DEFB124* **(Figure 3A)**.

GSEA further revealed that patients who developed VAP had lower expression of pathways

related to antibacterial immune responses including neutrophil degranulation, toll-like receptor

signaling, IL-17 signaling, antigen presentation and complement pathways and higher expression

of IFN-alpha/beta signaling pathways, more than two weeks before the onset of VAP **(Figure 3B)**.

Additionally, pathways related to adaptive immunity such as T and B cell receptor signaling were

also downregulated in patients who subsequently developed VAP **(Figure 3B)**.

To gauge the degree of immune signaling suppression compared to controls, we

performed a similar analysis on critically ill intubated patients without infection **(Figure 3C)**.

Relative to the control group, multiple antibacterial immune pathways were downregulated in

COVID-19 patients, with the greatest attenuation in the VAP group **(Figure 3C)**. Upstream

regulator analysis identified impaired activation of diverse cytokines in those with VAP, while

IFNB1 was notably upregulated **(Figure 3D)**. Several pro-inflammatory cytokines were

downregulated in both groups compared to the controls **(Figure S1)**. We expanded the

comparison at the "early" time-point to include patients with culture-negative VAP (VAP: n=6, No-

VAP: n=11) and observed similar differences at the pathway level **(Figure S2)**.

Given prior reports demonstrating correlation between SARS-CoV-2 viral load and

interferon related gene expression*(14)* we next asked whether viral load differed between VAP

and No-VAP patients. No differences in SARS-CoV-2 qPCR or viral reads per million (rpM) in bulk

RNA-seq data were found in the days following intubation (P = 0.84 (RNA-seq), P = 0.53 (PCR),

Figure S3). We also considered the possibility that differences in the number of days of steroid

exposure prior to sample collection might explain results, but found no differences (P = 0.343)

(Table S1).

COVID-19 VAP is associated with impaired anti-bacterial immune signaling in monocytes,

macrophages and neutrophils

To further understand the mechanism of early downregulation of key pathways involved

in antibacterial responses, we next asked whether this was driven by any one local immune cell

type. We performed scRNA-seq on TA specimens obtained early during disease course (median

of nine days before VAP) and enriched for immune cells using CD45 selection **(Methods)**.

Clustering based upon cellular transcriptional signatures indicated that monocytes, macrophages

and neutrophils were the most abundant cell types (**Figure 4A, S4A**) and thus we focused

transcriptional assessment on these populations. A comparison of cell type proportions did not

reveal statistically significant differences in populations of mono/macs, neutrophils or T cells in

COVID-19 patients who subsequently developed VAP **(Figure 4B**).

COVID-19 patients who developed VAP had distinct cell type-specific transcriptional

signatures compared to those without VAP at this "early" post-intubation time-point **(Figure 4, S5,**

S6). With respect to mono/macs and neutrophils, we identified 532 and 693 differential expressed

genes, respectively, at FDR< 0.05. Several genes with key roles in innate immunity were

downregulated in both cell types in the COVID-19 patients who subsequently developed VAP

versus those who did not, including *IL1Rn*, *ICAM1*, *NFKB2*, and *ITGAX* in neutrophils, as well as

the neutrophil chemokines *CXCL2 and CXCL8* in mono/macs (**Figure 4C, 4F, S5**). In addition,

similar to the bulk RNA-seq results demonstrating upregulation of type I IFN signaling at this time-

point in patients who developed VAP, we noted upregulation of several interferon-induced genes

including IFI27 and IFI30 in mono/macs, and IFI30, IFITM1, and IFITM3 in neutrophils **(Figure**

4C, F).

IPA canonical pathway analysis of gene expression within each cluster revealed
downregulation of several cytokine and innate immune signaling pathways in the patients who
later developed VAP at the "early" post-intubation time-point. In the mono/mac cluster, this
included downregulation of IL-1, IL-6, and iNOS signaling, as well as Th17 and TNFR2 signaling
(**Figure 4D)**. Analysis of the neutrophil cluster also demonstrated attenuated IL-1, IL-6, and
TNFR2 signaling and NF-κB pathways (**Figure 4G)**. COVID-19 patients who subsequently
developed VAP demonstrated upregulation of oxidative phosphorylation and glutathione
detoxification in the mono/mac subset, and interferon signaling, oxidative phosphorylation and
EIF2 signaling in the neutrophil cluster. Computational prediction of upstream cytokine activation
by IPA revealed impaired activation of multiple pro-inflammatory cytokines in both the mono/macs
and neutrophils in patients who developed VAP, including TNF, CXCL8, and IL1B, as well as
downregulation of key factors important in monocyte to macrophage differentiation (*CSF2*, *CSF3*,
PF4) **(Figure 4E, H)**.

In the T cell population, we identified 1318 differentially expressed genes at FDR < 0.05.
Genes associated with T cell recruitment, including *CXCR6, ITGA1* and *ITGA4*, which have been
shown to regulate localization and retention of T cells in the lung during viral infection*(15, 16)*,
were downregulated in patients with VAP. Additionally, genes indicative of T cell activation (*CD69,*
CD96, LAG3, ICOS, CD27), signaling (*CD3, ZAP70, ITK, CD8A, CD8B*), and effector functions
(*IFNG, GZMA, GZMB, KLRG1*) were significantly downregulated in patients with VAP, suggesting
an impairment in T cell responses **(Figure S6A)**. IPA revealed downregulation of signaling
pathways crucial for T cell recruitment, such as integrin signaling, and activation, such as CD28
signaling in helper T cells and phospholipase C signaling **(Figure S6B)**.

Temporal dynamics of the host response in COVID-19 patients who develop VAP
We next investigated temporal dynamics of the lower airway host inflammatory response
in COVID-19 patients from the time of intubation to development of VAP by evaluating differential

gene expression between COVID-19 VAP patients at the "early" time point (median of 17 days

before VAP onset, n=4) versus "late" time point (median of two days before VAP onset, n=5) by

bulk RNA-seq. We identified 2705 differentially expressed genes (FDR<0.1) and unsupervised

hierarchical clustering of the 50 most significant genes demonstrated clear separation of the two

time-points **(Figure 5A)**. GSEA revealed that type I interferon signaling was notably

downregulated at the "late" time-point most immediately preceding VAP onset in comparison to

the "early" timepoint **(Figure 5B)**; however, expression was still significantly higher than in the

No-VAP patients **(Figure 2B)**. Several other immune signaling pathways were more highly

expressed at this "late" time-point, presumably reflecting activation of an antibacterial response

in the setting of bacterial pneumonia **(Figure 5B)**. Consistent with this, upstream regulator

analysis indicated increased activation of several pro-inflammatory cytokines and decreased

IFNα and IFN-λ signaling at the "late" versus "early" time-points **(Figure 5C)**.

In contrast, comparing No-VAP patients at the "early" (n=8) versus "late" (n=8) time-points

yielded only two genes with a padj <0.1, both of which were interferon-stimulated genes (*RSAD2*

and *CMPK2*) downregulated at the "late" time-point, suggesting that while the host response was

relatively unchanged in these patients, the antiviral response attenuated over time. Indeed, GSEA

revealed that type I interferon signaling, and other antiviral immune pathways were downregulated

in the patients who did not develop VAP at the later time-point **(Figure S7)**.

Next, we performed a similar comparison between the "early" and "late" time-points based

on scRNA-seq data from patients who developed VAP. Differential gene expression analysis on

these two populations identified 1368 differentially expressed genes (FDR<0.05) in the mono/mac

cluster, and 1028 in the neutrophil cluster. IPA revealed upregulation of antibacterial signaling

pathways at the later time-point, including signaling by several cytokines in the mono/mac cluster

(IL-17, IL-6, IL-1, TNF, IL-23, IFN) **(Figure 5D-E)**, congruent with the bulk RNA-seq analysis.

Furthermore, we identified 1397 differentially expressed genes (FDR < 0.05) in the T cell cluster

between the two time-points and noted upregulation of signaling pathways indicative of an active

T cell response*(17)* (e.g. ERK/MAPK, Tec kinase, and phospholipase C) in the days preceding

VAP, which was also in agreement with the bulk RNA-seq results (**Figure S6C**).

We further assessed dynamics of host immune responses between VAP and No-VAP

patients by performing longitudinal analyses of key immune signaling pathways, including all

patients with available TA samples (VAP n=7, No-VAP n=10). Onset of VAP in these patients

ranged from 10-39 days post intubation, with a median of 25 days, and treatment with

immunosuppressants did not differ significantly between VAP and no-VAP patients (p=0.304,

Fisher's exact test). We calculated pathway Z-scores for each sample by averaging Z-scores for

the top 20 leading edge genes of each pathway (**Methods**). Early attenuation of immune signaling

in the VAP group was conspicuous, and this pattern eventually resolved later in disease course

by the time secondary bacterial infection became established **(Figures 5E-H)**. We confirmed that

the observed differences between VAP and no-VAP patients were not driven by differences in

treatment with immunosuppressants by comparing pathway Z-scores in patients that received

immunosuppressants and those that did not at the early time-point regardless of VAP group

(Figure S8).

Lung microbiome disruption precedes VAP in COVID-19 patients

We hypothesized that the innate immune suppression in patients who developed VAP

would correlate with viral load. Using TA metatranscriptomics to assess the lower respiratory

microbiome, we evaluated longitudinal changes in SARS-CoV-2 abundance. Although no

difference was observed at the "early" timepoint **(Figure S3)**, the trajectory of SARS-CoV-2 viral

load differed significantly in patients who developed VAP (p=0.0058), although in both groups

decreased over time (**Figure 6A**). This result suggested that COVID-19 patients who develop

VAP may exhibit impaired ability to clear virus compared to those who do not, and that the lung

microbiome composition may be similarly impacted.

Indeed, COVID-19 patients who developed VAP exhibited a significant reduction in

bacterial diversity of their airway microbiome up to three weeks before clinical signs of infection

(Shannon Diversity Index, p=0.012; **Figure 6B**). COVID-19 patients who developed VAP also had

lower airway microbiome compositions more closely resembling each other than those from

patients who did not develop VAP, across all timepoints since intubation (Bray Curtis index,

p=0.0033; **Figure 6C**), suggesting community collapse precedes the development of VAP. All

patients received antibiotics prior to collection of the first sample, suggesting that antibiotic use

was not driving these differences **(Table S1)**.

Discussion

Secondary bacterial pneumonia contributes to significant morbidity and mortality in

patients with primary viral lower respiratory tract infections*(1, 3)*, but mechanisms governing

individual susceptibility to VAP have remained unclear. Few human cohort studies have evaluated

the immunologic underpinnings of VAP, and none have been reported in the context of COVID-

19, which is characterized by a dysregulated host response distinct from other viral

pneumonias*(14, 18, 19)*. To address this gap and probe mechanisms of VAP susceptibility in

patients with COVID-19, we carried out a systems biological assessment of host and microbial

dynamics of the lower respiratory tract.

Two days before VAP onset, a transcriptional signature consistent with bacterial infection

was observed. This finding suggests that host response changes can occur before clinical

recognition of pneumonia, highlighting the potential utility of the host transcriptome as a tool for

VAP surveillance. While intriguing, this observation did not provide an explanation for differential

susceptibility of some COVID-19 patients to post-viral pneumonia.

The discovery of an early suppressed antibacterial immune response in patients who later

developed VAP did however, offer a potential explanation. More than two weeks before VAP

onset, we observed a striking suppression of pathways related to both innate and adaptive

immunity, including neutrophil degranulation, TLR signaling, complement activation, antigen presentation, and T cell receptor and B receptor signaling, as well as cytokine signaling (e.g. IL-1, IL-4, IL-12, IL-13 and IL-17). Comparison against uninfected, intubated controls confirmed the previously described paradoxical impairment in immune signaling found in patients with severe COVID-19[18], and suggested that VAP susceptibility may be the result of disproportionate suppression of innate and adaptive pathways critical for antibacterial defense, resulting in enhanced susceptibility to opportunistic secondary infections.

Animal models of influenza have provided insight into potential mechanisms of post-viral pneumonia, although none have provided insight regarding why some individuals are more susceptible than others. In mice inoculated with influenza, for instance, virus-induced type I IFN suppresses neutrophil chemokines and impairs Th17 immunity, compromising effective clearance of bacterial infections[9, 10]. Interestingly, we also observed increased type I interferon signaling in COVID-19 patients who weeks later developed VAP, and a strikingly similar impairment in Th17 signaling and other immune pathways. Desensitization to toll-like receptor (TLR) ligands after influenza infection has also been documented[20], which is congruent with the downregulation of TLR signaling at the time of intubation observed in our bulk RNA-seq analyses.

Impaired bacterial clearance by alveolar macrophages was found to be driven by virus-related IFNγ production by T cells[21] in a murine post-influenza model. In contrast, we found that T cells from patients who later developed VAP expressed lower levels of IFNγ at the time of intubation. This difference may relate to species-specific variations in immune signaling or intrinsic differences in the host response to influenza virus versus SARS-CoV-2[14, 18].

We asked whether certain cell types were responsible for driving the early suppression of immune signaling observed in COVID-19 patients who went on to develop VAP. No significant differences in proportions of the most abundant cell types - monocytes/macrophages, neutrophils or T cells – was observed between patients with or without VAP at the time of intubation. This

finding suggests that an impairment of immune cell recruitment was not causing these differences,

but rather significant gene expression differences within each of these immune cell populations.

In both the mono/mac and neutrophil populations, we observed broad downregulation of

the innate immune response, and initiation of the adaptive immune response, concordant with

global observations in bulk RNA-seq analyses. Further analysis revealed a downregulation of

monocyte to macrophage differentiation and neutrophil chemotaxis. Further, we noted a

downregulation of key pathways and transcription factors involved in antimicrobial immune

responses including iNOS in mono/macs, as well as NFKB and TREM1 in mono/macs and

neutrophils. Both bulk and scRNA-seq suggested an impairment in T cell recruitment, signaling,

and effector functions. Overall, our data suggest that while no difference in cell type populations

existed between groups, changes in the gene expression of mono/macs, neutrophils and T cells

contributes to immune suppression in COVID-19 patients who later develop VAP.

SARS-CoV-2 viral load correlates with interferon stimulated gene expression *(14, 18)* and

thus we initially hypothesized that differences in viral load between groups might relate to

individual VAP susceptibility. However, we found no difference between groups at the "early"

timepoint. Moreover, no differences existed in terms of immunosuppressive medication

administration or clinically diagnosed immunodeficiency, suggesting that other, still unidentified

mechanisms present at the time of intubation must underlie the marked suppression of immune

gene expression in COVID-19 patients who went on to develop VAP.

While no difference in viral load was observed at the time of intubation, the COVID-19

patients who developed VAP exhibited impaired viral clearance over the time-course of intubation.

This observation was corroborated by a prolonged antiviral type I interferon response at the "late"

timepoint (median of two days before VAP onset) in patients who developed VAP versus those

who did not, pointing to the persistence of suboptimal antiviral immunity in these patients. Early

induction of functional SARS-CoV-2 specific T cells is associated with faster viral clearance in

COVID-19 patients*(22)* and likewise, we observed impairments in T cell activation and signaling

in the VAP group, which further suggests a decreased ability to control the virus in these patients.

Respiratory viruses can reshape the human airway microbiome by modulating host

inflammatory responses*(23, 24)*. In mouse models of influenza, the airway microbiome exhibits

expansion of several bacterial families during the course of viral infection as innate immunity is

suppressed*(23)*. These changes increase the risk of secondary bacterial infection*(23)* and have

been observed in patients with chronic obstructive pulmonary disease, where suppression of the

innate immune response in rhinovirus infected patients may be followed by bacterial

superinfection*(25, 26)*.

Similarly, the innate immune suppression observed in COVID-19 patients who developed

VAP was associated with airway microbiome collapse and the outgrowth of lung pathogens in

advance of clinical VAP diagnosis. This finding suggests that individual immune responses to

SARS-CoV-2 infection may drive a restructuring of the microbial community and increase

susceptibility to VAP (**Figure 7**). The resulting outgrowth of a VAP-associated bacterial pathogen

may elicit an antibacterial response, but the broader immunosuppressive state preceding this

response may be insufficient to control the development of clinical pneumonia. Those with a

lesser degree of immunosuppression may be able to respond faster and therefore control

opportunistic bacterial pathogens more effectively.

These findings may also have important implications for management of patients with

COVID-19 related acute respiratory failure, many of whom are now being treated with

corticosteroids plus/minus IL-6 receptor blocking agents. These agents may lead to further

suppression of the key pathways required for host response to secondary bacterial infection.

Thus, our results emphasize the need for ongoing vigilance for VAP in patients treated with potent

immunosuppressive agents, as well as the need to develop novel diagnostic and/or prognostic

approaches to identifying patients at highest risk. For instance, availability of molecular

biomarkers to assess a patient's risk of VAP at the time of intubation could reduce inappropriate

use of prophylactic antibiotics or immunomodulatory treatments, or signal a need for enhanced

surveillance strategies. Signatures of immune dysfunction have been used as biomarkers to

predict nosocomial infection in critically ill patients,*(27)* although not in the context of viral

infection.

Sample size is a limitation of this study; however, the reproducibility of our observations

across both bulk and scRNA-seq analyses and the significant number of differentially expressed

genes among the comparator groups support the validity of our conclusions. Because this study

was limited to critically ill, intubated patients, we were unable to assess early stages of COVID-

19, which may provide additional insight regarding determinants of secondary bacterial infection.

Additionally, we were unable to assess whether epithelial cells contributed to VAP risk due to

enrichment for immune cells prior to scRNA-seq. With larger cohorts, the early detection of

specific immune pathway suppression and microbiome collapse could be leveraged to develop

clinically useful models for identifying COVID-19 patients with increased susceptibility to

secondary bacterial pneumonia.

Materials and Methods

Study design and clinical cohort

We conducted a prospective case-control study of adults requiring mechanical ventilation

for COVID-19 or for other reasons in the absence of pulmonary infection (**Figure 1**). We studied

patients who were enrolled in either of two prospective cohort studies of critically ill patients at the

University of California, San Francisco (UCSF) and Zuckerberg San Francisco General Hospital.

Both studies were approved by the UCSF Institutional Review Board under protocols 17-24056

and 20-30497, respectively, which granted a waiver of initial consent for tracheal aspirate and

blood sampling. Informed consent was subsequently obtained from patients or their surrogates

for continued study participation, as previously described*(11)*. Tracheal aspirate (TA) was

collected and processed for either bulk RNA-seq or scRNA-seq as described below. Of the

COVID-19 patients, 19 were co-enrolled in the National Institute of Allergy and Infectious

Diseases-funded Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) Network

study. IMPACC is a multicenter study that employs a systems biology approach to identify host

immunologic and viral determinants of COVID-19 pathophysiology and disease severity.

Ventilator-associated pneumonia adjudication

A total of 84 adults who required intubation for severe COVID-19 (Cohort 1) and who had

available TA samples were considered for inclusion in the study (**Figure 1**). Patients who met the

Centers for Disease Control (CDC) definition for VAP*(13)* with a positive bacterial sputum culture

were adjudicated as having VAP for the purpose of the study (N=16); patients who did not meet

these criteria, and for whom there was no sustained clinical suspicion for bacterial pneumonia

during the admission, were categorized as No-VAP (N=17). VAP and No-VAP patients for whom

samples at the time-points of interest were available were included in the primary analyses (VAP:

N=10; No-VAP: N=13). Patients who met CDC-VAP criteria but had negative TA cultures were

included in a secondary supplementary analysis only (N=5). All other patients were excluded,

including patients with clinically-suspected bacterial pneumonia who did not meet CDC VAP

criteria. Eight intubated patients from a recent study*(18)* (Cohort 2) were included as controls and

were selected because they had previously been adjudicated as having no evidence of lower

respiratory tract infection. This group included four patients with non-infectious ARDS and four

patients with no ARDS who were intubated for other reasons (subdural hematoma (N=1),

retroperitoneal hemorrhage (N=1), or neurosurgical procedure (N=2)).

Tracheal aspirate sampling

Following enrollment, tracheal aspirate (TA) was collected (periodically following

intubation for Study 1, or once within 3 days of intubation for Study 2), without addition of saline

wash, and either a) mixed 1:1 with DNA/RNA shield (Zymo Research) for bulk RNA-seq or b)

immediately processed in a biosafety level 3 laboratory (BSL3) for scRNA-seq analysis.

Bulk RNA sequencing and host transcriptome analysis

RNA sequencing

To evaluate host and microbial gene expression, metatranscriptomic next generation RNA

sequencing (RNA-seq) was performed on TA specimens. Following RNA extraction (Zymo

Pathogen Magbead Kit) and DNase treatment, human cytosolic and mitochondrial ribosomal RNA

was depleted using FastSelect (Qiagen). To control for background contamination, we included

negative controls (water and HeLa cell RNA) as well as positive controls (spike-in RNA standards

from the External RNA Controls Consortium (ERCC)) *(28)*. RNA was then fragmented and

underwent library preparation using the NEBNext Ultra II RNA-seq Kit (New England BioLabs).

Libraries underwent 146 nucleotide paired-end Illumina sequencing on an Illumina Novaseq 6000.

Host differential expression

Following demultiplexing, sequencing reads were pseudo-aligned with kallisto *(29)* to an

index consisting of all transcripts associated with human protein coding genes (ENSEMBL v. 99),

cytosolic and mitochondrial ribosomal RNA sequences and the sequences of ERCC RNA

standards. Gene-level counts were generated from the transcript-level abundance estimates

using the R package tximport *(30)*, with the scaledTPM method. Samples retained in the dataset

had a total of at least 1,000,000 estimated counts associated with transcripts of protein coding

genes.

Genes were retained for differential expression analysis if they had counts in at least 30%

of samples. Differential expression analysis was performed using the R package DESeq2 *(31)*.

We modeled the expression of individual genes using the design formula ~VAPgroup, where VAP

groups were "VAP-early", "No VAP-early", "VAP-late" and "No VAP-late" and used the results()

function to extract a specific contrast. Separate comparisons to the control group were performed

using the design formula ~COVID-19-status to compare positive and negative patients.

Significant genes were identified using a Benjamini-Hochberg false discovery rate (FDR)

< 0.1. We generated heatmaps of the top 50 differentially expressed genes by FDR. For

visualization, gene expression was normalized using the regularized log transformation, centered,

and scaled prior to clustering. Heatmaps were generated using the *pheatmap* package. Columns

were clustered using Euclidean distance and rows were clustered using Pearson correlation.

Differential expression analysis results are provided in (**Supplementary data file 1**).

Pathway analysis

Gene set enrichment analyses (GSEA) were performed using the fgseaMultilevel function

in the R package fgsea*(32)* and REACTOME pathways*(33)* with a minimum size of 10 genes and

a maximum size of 1,500 genes. All genes were included in the comparison, pre-ranked by the

test statistic. Significant pathways were defined as those with a Benjamini-Hochberg adjusted p-

value < 0.05. Ingenuity Pathway Analysis (IPA) Canonical Pathway and Upstream Regulator

Analysis*(34)* was employed on genes with p<0.1 and ranked by the test statistic to identify

cytokine regulators. Significant IPA results were defined as those with a Z-score absolute value

greater than 2 and an overlap P value < 0.05. The gene sets in figures were selected to reduce

redundancy and highlight diverse biological functions. Full GSEA and IPA results are provided in

(**Supplementary data files 2 and 3**).

Longitudinal pathway analysis was performed using all available TA samples spanning

post-intubation to VAP onset for all patients included in the bulk RNA-seq analysis. Analysis was

restricted to samples with at least 1,000,000 human protein coding transcripts. Pathways of

interest were selected from the significant GSEA results of the comparison of VAP vs. No-VAP

patients in the "early" time-point. The top 20 leading edge genes were selected from each pathway

for analysis. To calculate a Z-score for each gene, expression was normalized using the variance

stabilizing transformation (VST), centered, and scaled. A pathway Z-score was calculated by

averaging the 20 gene Z-scores. Multiple Z-scores per patient at a given time interval were

averaged so that each patient corresponds to one datapoint at each interval. Statistical

significance of pathway expression over time between VAP and No-VAP groups was calculated

using a two-way analysis of variance (ANOVA) in GraphPad PRISM.

Single cell RNA sequencing and transcriptome analysis

After collection, fresh TA was transported to a BSL-3 laboratory at ambient temperature

to improve neutrophil survival. 3mL of TA was dissociated in 40mL of PBS with 50ug/mL

collagenase type 4 (Worthington) and 0.56 ku/mL of Dnase I (Worthington) for 10 minutes at room

temperature, followed by passage through a $70\mu M$ filter. Cells were pelleted at 350g 4C for 10

minutes, resuspended in PBS with 2mM EDTA and 0.5% BSA, and manually counted on a

hemocytometer. Cells were stained with MojoSort Human CD45 and purified by the

manufacturer's protocol (Biolegend). After CD45 positive selection, cells were manually counted

with trypan blue on a hemocytometer. Using a V(D)J v1.1 kit according to the manufacturer's

protocol, samples were loaded on a 10X Genomics Chip A without multiplexing, aiming to capture

10,000 cells (10X Genomics). Libraries underwent paired end 150 base pair sequencing on an

Illumina NovaSeq6000.

Raw sequencing reads were aligned to GRCh38 using the STAR aligner *(35)*. Cell

barcodes were then determined based upon UMI count distribution. Read count matrices were

generated through the 10X genomics cellranger pipeline v3.0. Data was processed and analyzed

using the Scanpy v1.6 *(36)*. Cells that had <200 genes and had greater than 30,000 counts were

filtered. Mitochondrial genes were removed and multi-sample integration was performed using

Harmony v0.1.4 *(37)*. Differential expression was performed using MAST v1.16.0 *(38)*. Due to the

significantly greater number of differentially expressed genes in scRNA-seq analyses, we used a

more restrictive cutoff of FDR < 0.05 for significant genes. Differential expression analysis results

are detailed in (**Supplementary data file 4**).

<u>Pathway analysis</u>

Ingenuity Pathway Analysis (IPA) Canonical Pathway and Upstream Regulator

Analysis*(34)* was employed on genes with p<0.05 and ranked by log2foldchange to identify

canonical pathways and cytokine regulators. We utilized a more restrictive p value cutoff for

scRNA-seq to ensure a similar number of genes were input into IPA. Significant IPA results were

defined as those with a Z-score absolute value greater than 2 and an overlap P value < 0.05. The

gene sets in figures were selected to reduce redundancy and highlight diverse biological

functions. Full GSEA and IPA results are provided in (**Supplementary data files 5 and 6**).

Lung microbiome analysis

RNA from tracheal aspirates was sequenced as described above. Respiratory microbiome

sequences were quality-filtered, human reads removed, and assembled using open-source

IDseq pipeline*(39, 40)*, which performs reference based taxonomic alignment at both the

nucleotide and amino acid level against sequences in the National Center for Biotechnology

Information (NCBI) nucleotide (NT) and non-redundant (NR) databases, followed by assembly of

the reads matching each taxon detected. Taxonomic alignments underwent background

correction for environmental contaminants (see below), viruses were excluded, and data was then

aggregated to the genus level before calculating diversity metrics. Alpha diversity (Shannon's

Diversity Index) and beta diversity (Bray-Curtis dissimilarity) were calculated and the latter plotted

using non-metric multidimensional scaling (NDMS). Comparison of alpha and beta diversity over

time between VAP and No-VAP groups was calculated using a two-way analysis of variance

(ANOVA) in GraphPad PRISM.

<u>Identification and mitigation of environmental contaminants</u>

To minimize inaccurate taxonomic assignments due to environmental and reagent derived

contaminants, non-templated "water only" and HeLa cell RNA controls were processed with each

group of samples that underwent nucleic acid extraction. These were included, as well as positive

control clinical samples, with each sequencing run. Negative control samples enabled estimation

of the number of background reads expected for each taxon. A previously developed negative

binomial model *(14)* was employed to identify taxa with NT sequencing alignments present at an

abundance significantly greater compared to negative water controls. This was done by modeling

the number of background reads as a negative binomial distribution, with mean and dispersion

fitted on the negative controls. For each batch (sequencing run) and taxon, we estimated the

mean parameter of the negative binomial by averaging the read counts across all negative

controls, slightly regularizing this estimate by including the global average (across all batches) as

an additional sample. We estimated a single dispersion parameter across all taxa and batches,

using the functions glm.nb() and theta.md() from the R package MASS *(41)*. Taxa that achieved a

p-value <0.01 were carried forward.

Supplementary Materials

Supplementary Figures

Figure S1: Regulation of cytokines at the "early" time-point with respect to a baseline of

uninfected, intubated controls.

Figure S2: Gene set enrichment analysis at the "early" time-point with an expanded definition of

VAP to include culture-negative VAP cases.

Figure S3: SARS-CoV-2 viral load in VAP and No-VAP patients from the "early" time-point

samples.

Figure S4: Single cell RNA-seq density plots comparing VAP and no-VAP patients at the "early"

time-point.

Figure S5: Heatmap depicting differential expression of the top 50 differentially expressed genes

in monocytes/macrophages and neutrophils.

Figure S6: T cell gene expression and gene set enrichment analysis.

Figure S7: Gene set enrichment analysis comparing patients who do not develop VAP at the

"early" versus "late" time-points.

Figure S8: Immune pathway expression in patients who were treated with immunosuppressants

compared to those who were not at the "early" time-point.

Supplementary Tables

Table S1: Clinical and demographic data for patients in bulk RNA-seq analyses.

Table S2: Clinical and demographic data for patients in single cell RNA-seq analyses.

Table S3: Details of immunosuppressant use for all patients.

Supplementary Data Files

Data file S1: Differentially expressed genes in bulk RNA-seq analyses.

Data file S2: Gene set enrichment analysis results from bulk RNA-seq analyses.

Data file S3: Ingenuity pathway analysis for upstream regulators from bulk RNA-seq analyses.

Data file S4: Differentially expressed genes in single cell RNA-seq analyses.

Data file S5: Ingenuity pathway analysis for canonical pathways from single cell RNA-seq

analyses.

Data file S6: Ingenuity pathway analysis for upstream regulators from single cell RNA-seq

analyses.

Data file S7: Detailed clinical and demographic data for COVID-19 patients.

Supplementary Appendix: COMET Consortium Member list.

References

1. A. R. Falsey, K. L. Becker, A. J. Swinburne, E. S. Nylen, M. A. Formica, P. A. Hennessey, M. M. Criddle, D. R. Peterson, A. Baran, E. E. Walsh, Bacterial Complications of Respiratory Tract Viral Illness: A Comprehensive Evaluation, *The Journal of Infectious Diseases* **208**, 432–441 (2013).

2. D. M. Morens, J. K. Taubenberger, A. S. Fauci, Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness, *J Infect Dis* **198**, 962–970 (2008).

3. A. Rouzé, I. Martin-Loeches, P. Povoa, D. Makris, A. Artigas, M. Bouchereau, F. Lambiotte, M. Metzelard, P. Cuchet, C. Boulle Geronimi, M. Labruyere, F. Tamion, M. Nyunga, C.-E. Luyt, J. Labreuche, O. Pouly, J. Bardin, A. Saade, P. Asfar, J.-L. Baudel, A. Beurton, D. Garot, I. Ioannidou, L. Kreitmann, J.-F. Llitjos, E. Magira, B. Mégarbane, D. Meguerditchian, E. Moglia, A. Mekontso-Dessap, J. Reignier, M. Turpin, A. Pierre, G. Plantefeve, C. Vinsonneau, P.-E. Floch, N. Weiss, A. Ceccato, A. Torres, A. Duhamel, S. Nseir, Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study, *Intensive Care Med* , 1–11 (2021).

4. C.-E. Luyt, T. Sahnoun, M. Gautier, P. Vidal, S. Burrel, M. Pineton de Chambrun, J. Chommeloux, C. Desnos, J. Arzoine, A. Nieszkowska, N. Bréchot, M. Schmidt, G. Hekimian, D. Boutolleau, J. Robert, A. Combes, J. Chastre, Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study, *Ann Intensive Care* **10**, 158 (2020).

5. T. Bardi, V. Pintado, M. Gomez-Rojo, R. Escudero-Sanchez, A. Azzam Lopez, Y. Diez-Remesal, N. Martinez Castro, P. Ruiz-Garbajosa, D. Pestaña, Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome, *Eur J Clin Microbiol Infect Dis* (2021), doi:10.1007/s10096-020-04142-w.

6. M. Maes, E. Higginson, J. Pereira-Dias, M. D. Curran, S. Parmar, F. Khokhar, D. Cuchet-Lourenço, J. Lux, S. Sharma-Hajela, B. Ravenhill, I. Hamed, L. Heales, R. Mahroof, A. Solderholm, S. Forrest, S. Sridhar, N. M. Brown, S. Baker, V. Navapurkar, G. Dougan, J. Bartholdson Scott, A. Conway Morris, Ventilator-associated pneumonia in critically ill patients with COVID-19, *Crit Care* **25**, 25 (2021).

7. K. K. Søgaard, V. Baettig, M. Osthoff, S. Marsch, K. Leuzinger, M. Schweitzer, J. Meier, S. Bassetti, R. Bingisser, C. H. Nickel, N. Khanna, S. Tschudin-Sutter, M. Weisser, M. Battegay, H. H. Hirsch, H. Pargger, M. Siegemund, A. Egli, Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia, *J Intensive Care* **9** (2021), doi:10.1186/s40560-021-00526-y.

8. D. W. Metzger, K. Sun, Immune Dysfunction and Bacterial Co-Infections following Influenza, *J Immunol* **191**, 2047–2052 (2013).

9. A. Shahangian, E. K. Chow, X. Tian, J. R. Kang, A. Ghaffari, S. Y. Liu, J. A. Belperio, G. Cheng, J. C. Deng, Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice, *J Clin Invest* **119**, 1910–1920 (2009).

10. A. Kudva, E. V. Scheller, K. M. Robinson, C. R. Crowe, S. M. Choi, S. R. Slight, S. A.
Khader, P. J. Dubin, R. I. Enelow, J. K. Kolls, J. F. Alcorn, Influenza A inhibits Th17-mediated
host defense against bacterial pneumonia in mice, *J Immunol* **186**, 1666–1674 (2011).

11. C. Langelier, K. L. Kalantar, F. Moazed, M. R. Wilson, E. D. Crawford, T. Deiss, A. Belzer,
S. Bolourchi, S. Caldera, M. Fung, A. Jauregui, K. Malcolm, A. Lyden, L. Khan, K. Vessel, J.
Quan, M. Zinter, C. Y. Chiu, E. D. Chow, J. Wilson, S. Miller, M. A. Matthay, K. S. Pollard, S.
Christenson, C. S. Calfee, J. L. DeRisi, Integrating host response and unbiased microbe
detection for lower respiratory tract infection diagnosis in critically ill adults, *Proc Natl Acad Sci*
U S A **115**, E12353–E12362 (2018).

12. J. L. Flanagan, E. L. Brodie, L. Weng, S. V. Lynch, O. Garcia, R. Brown, P. Hugenholtz, T.
Z. DeSantis, G. L. Andersen, J. P. Wiener-Kronish, J. Bristow, Loss of bacterial diversity during
antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa, *J Clin*
Microbiol **45**, 1954–1962 (2007).

13. CDC-NHSN, Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated
Pneumonia [PNEU]) Event (available at
https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf).

14. E. Mick, J. Kamm, A. O. Pisco, K. Ratnasiri, J. M. Babik, G. Castañeda, J. L. DeRisi, A. M.
Detweiler, S. L. Hao, K. N. Kangelaris, G. R. Kumar, L. M. Li, S. A. Mann, N. Neff, P. A. Prasad,
P. H. Serpa, S. J. Shah, N. Spottiswoode, M. Tan, C. S. Calfee, S. A. Christenson, A. Kistler, C.
Langelier, Upper airway gene expression reveals suppressed immune responses to SARS-
CoV-2 compared with other respiratory viruses, *Nature Communications* **11**, 5854 (2020).

15. A. N. Wein, S. R. McMaster, S. Takamura, P. R. Dunbar, E. K. Cartwright, S. L. Hayward, D.
T. McManus, T. Shimaoka, S. Ueha, T. Tsukui, T. Masumoto, M. Kurachi, K. Matsushima, J. E.
Kohlmeier, CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways,
Journal of Experimental Medicine **216**, 2748–2762 (2019).

16. M. Grau, S. Valsesia, J. Mafille, S. Djebali, M. Tomkowiak, A.-L. Mathieu, D. Laubreton, S.
de Bernard, P.-E. Jouve, E. Ventre, L. Buffat, T. Walzer, Y. Leverrier, J. Marvel, Antigen-
Induced but Not Innate Memory CD8 T Cells Express NKG2D and Are Recruited to the Lung
Parenchyma upon Viral Infection, *The Journal of Immunology* **200**, 3635–3646 (2018).

17. J. E. Smith-Garvin, G. A. Koretzky, M. S. Jordan, T cell activation, *Annu Rev Immunol* **27**,
591–619 (2009).

18. A. Sarma, S. Christenson, E. Mick, T. Deiss, C. DeVoe, A. Pisco, R. Ghale, A. Jauregui, A.
Byrne, F. Moazed, N. Spottiswoode, P. Sinha, B. Zha, N. Neff, M. Tan, P. H. Serpa, K. M.
Ansel, J. Wilson, A. Leligdowicz, E. Seigel, M. Sirota, J. DeRisi, M. Matthay, C. Consortium, C.
Hendrickson, K. Kangelaris, M. Krummel, P. Woodruff, D. Erle, C. Calfee, C. Langelier, COVID-
19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and
is modified by dexamethasone, *Res Sq* (2021), doi:10.21203/rs.3.rs-141578/v1.

19. Blanco-Melo, Daniel, Imbalanced host response to SARS-CoV-2 drives development of
COVID-19, *Cell.* , doi:10.1016/j.cell.2020.04.026.

20. A. Didierlaurent, J. Goulding, S. Patel, R. Snelgrove, L. Low, M. Bebien, T. Lawrence, L. S.
van Rijt, B. N. Lambrecht, J.-C. Sirard, T. Hussell, Sustained desensitization to bacterial Toll-like

receptor ligands after resolution of respiratory influenza infection, *J Exp Med* **205**, 323–329
(2008).

21. K. Sun, D. W. Metzger, Inhibition of pulmonary antibacterial defense by interferon-gamma
during recovery from influenza infection, *Nat Med* **14**, 558–564 (2008).

22. A. T. Tan, M. Linster, C. W. Tan, N. Le Bert, W. N. Chia, K. Kunasegaran, Y. Zhuang, C. Y.
L. Tham, A. Chia, G. J. D. Smith, B. Young, S. Kalimuddin, J. G. H. Low, D. Lye, L.-F. Wang, A.
Bertoletti, Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral
clearance and mild disease in COVID-19 patients, *Cell Reports* **34**, 108728 (2021).

23. J. Goulding, A. Godlee, S. Vekaria, M. Hilty, R. Snelgrove, T. Hussell, Lowering the
Threshold of Lung Innate Immune Cell Activation Alters Susceptibility to Secondary Bacterial
Superinfection, *J Infect Dis* **204**, 1086–1094 (2011).

24. W. H. Man, W. A. A. de Steenhuijsen Piters, D. Bogaert, The microbiota of the respiratory
tract: gatekeeper to respiratory health, *Nat Rev Microbiol* **15**, 259–270 (2017).

25. P. Mallia, J. Footitt, R. Sotero, A. Jepson, M. Contoli, M.-B. Trujillo-Torralbo, T. Kebadze, J.
Aniscenko, G. Oleszkiewicz, K. Gray, S. D. Message, K. Ito, P. J. Barnes, I. M. Adcock, A. Papi,
L. A. Stanciu, S. L. Elkin, O. M. Kon, M. Johnson, S. L. Johnston, Rhinovirus Infection Induces
Degradation of Antimicrobial Peptides and Secondary Bacterial Infection in Chronic Obstructive
Pulmonary Disease, *Am J Respir Crit Care Med* **186**, 1117–1124 (2012).

26. P. L. Molyneaux, P. Mallia, M. J. Cox, J. Footitt, S. A. G. Willis-Owen, D. Homola, M.-B.
Trujillo-Torralbo, S. Elkin, O. M. Kon, W. O. C. Cookson, M. F. Moffatt, S. L. Johnston,
Outgrowth of the Bacterial Airway Microbiome after Rhinovirus Exacerbation of Chronic
Obstructive Pulmonary Disease, *Am J Respir Crit Care Med* **188**, 1224–1231 (2013).

27. A. Conway Morris, D. Datta, M. Shankar-Hari, J. Stephen, C. J. Weir, J. Rennie, J. Antonelli,
A. Bateman, N. Warner, K. Judge, J. Keenan, A. Wang, T. Burpee, K. A. Brown, S. M. Lewis, T.
Mare, A. I. Roy, G. Hulme, I. Dimmick, A. G. Rossi, A. J. Simpson, T. S. Walsh, Cell-surface
signatures of immune dysfunction risk-stratify critically ill patients: INFECT study, *Intensive Care*
Med **44**, 627–635 (2018).

28. P. S. Pine, S. A. Munro, J. R. Parsons, J. McDaniel, A. B. Lucas, J. Lozach, T. G. Myers, Q.
Su, S. M. Jacobs-Helber, M. Salit, Evaluation of the External RNA Controls Consortium (ERCC)
reference material using a modified Latin square design, *BMC Biotechnol* **16**, 54 (2016).

29. N. L. Bray, H. Pimentel, P. Melsted, L. Pachter, Near-optimal probabilistic RNA-seq
quantification, *Nature Biotechnology* **34**, 525–527 (2016).

30. C. Soneson, M. I. Love, M. D. Robinson, Differential analyses for RNA-seq: transcript-level
estimates improve gene-level inferences, *F1000Res* **4**, 1521 (2015).

31. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2, *Genome Biol* **15**, 550 (2014).

32. G. Korotkevich, V. Sukhov, A. Sergushichev, Fast gene set enrichment analysis, *bioRxiv* ,
060012 (2019).

33. D. Croft, A. F. Mundo, R. Haw, M. Milacic, J. Weiser, G. Wu, M. Caudy, P. Garapati, M.
Gillespie, M. R. Kamdar, B. Jassal, S. Jupe, L. Matthews, B. May, S. Palatnik, K. Rothfels, V.
Shamovsky, H. Song, M. Williams, E. Birney, H. Hermjakob, L. Stein, P. D'Eustachio, The
Reactome pathway knowledgebase, *Nucleic Acids Res* **42**, D472-477 (2014).

34. A. Krämer, J. Green, J. Pollard, S. Tugendreich, Causal analysis approaches in Ingenuity
Pathway Analysis, *Bioinformatics* **30**, 523–530 (2014).

35. A. Dobin, C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson,
T. R. Gingeras, STAR: ultrafast universal RNA-seq aligner, *Bioinformatics* **29**, 15–21 (2013).

36. F. A. Wolf, P. Angerer, F. J. Theis, SCANPY : large-scale single-cell gene expression data
analysis, *Genome Biology* **19**, 15 (2018).

37. I. Korsunsky, J. Fan, K. Slowikowski, F. Zhang, K. Wei, Y. Baglaenko, M. Brenner, P.-R.
Loh, S. Raychaudhuri, Fast, sensitive, and accurate integration of single cell data with Harmony,
bioRxiv , 461954 (2018).

38. G. Finak, A. McDavid, M. Yajima, J. Deng, V. Gersuk, A. K. Shalek, C. K. Slichter, H. W.
Miller, M. J. McElrath, M. Prlic, P. S. Linsley, R. Gottardo, MAST: a flexible statistical framework
for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA
sequencing data, *Genome Biol* **16**, 278 (2015).

39. A. Ramesh, S. Nakielny, J. Hsu, M. Kyohere, O. Byaruhanga, C. de Bourcy, R. Egger, B.
Dimitrov, Y.-F. Juan, J. Sheu, J. Wang, K. Kalantar, C. Langelier, T. Ruel, A. Mpimbaza, M. R.
Wilson, P. J. Rosenthal, J. L. DeRisi, Metagenomic next-generation sequencing of samples
from pediatric febrile illness in Tororo, Uganda, *PLoS One* **14**, e0218318 (2019).

40. K. L. Kalantar, T. Carvalho, C. F. A. de Bourcy, B. Dimitrov, G. Dingle, R. Egger, J. Han, O.
B. Holmes, Y.-F. Juan, R. King, A. Kislyuk, M. F. Lin, M. Mariano, T. Morse, L. V. Reynoso, D.
R. Cruz, J. Sheu, J. Tang, J. Wang, M. A. Zhang, E. Zhong, V. Ahyong, S. Lay, S. Chea, J. A.
Bohl, J. E. Manning, C. M. Tato, J. L. DeRisi, IDseq—An open source cloud-based pipeline and
analysis service for metagenomic pathogen detection and monitoring, *Gigascience* **9** (2020),
doi:10.1093/gigascience/giaa111.

41. W. N. Venables, B. D. Ripley, *Modern Applied Statistics with S* (Springer-Verlag, New York,
ed. 4, 2002; https://www.springer.com/gp/book/9780387954578).

Acknowledgements: This study was performed with support from the National Institute of Allergy

and Infectious Diseases-sponsored Immunophenotyping Assessment in a COVID-19 Cohort

(IMPACC) Network. We gratefully appreciate support from Amy Kistler, PhD, Jack Kamm, PhD,

Angela Deitweiller, PhD, Saharai Caldera, BS and Maira Phelps BS.

Funding: Funding for the COMET cohort enrollment, sample collection and data analysis derived

from: K23HL138461-01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), R35 HL140026

(CSC), NIAID U19AI077439 (DJE), Chan Zuckerberg Biohub (AB, JLD). The UCSF IMPACC site

was funded by NIAID U19AI077439 (DJE). Funding for enrollment of COMET participants not

enrolled in IMPACC and for all sample collection and data analysis derived from K23HL138461-

01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), R35 HL140026 (CSC), and the Chan

Zuckerberg Biohub (AB, JLD). Philanthropic support was provided from Mark and Carrie Casey,

Julia and Kevin Hartz, Carl Kawaja and Wendy Holcombe, Eric Keisman and Linda Nevin, Martin

and Leesa Romo, Three Sisters Foundation, Diana Wagner and Jerry Yang and Akiko Yamazaki.

Author contributions:

Conceptualization: CRL, AT, BSZ, AB, CD, SL, ER, OR, CSC

Methodology: CRL, AT, BSZ, AB, CD, SL, ER, OR

Data acquisition: RG, AJ, PHS, TJD, BSZ, AB, NJ

Formal analysis: AT, BSZ, AB, CD, SL, ER, EM

Investigation: BSZ, AB, CD, SS, CSC, DJE

Funding acquisition: CRL, CSC, JLD, DJE

Supervision: CRL, OR, NN, JLD, CSC, DJE

Writing - original draft: AT, BSZ, AB, CD, SL, ER, CRL

Writing - review & editing: All authors

Competing interests: Authors declare that they have no competing interests.

<u>Data and materials availability</u>: Host gene expression data are available under NCBI GEO

accession number GSE168019 for bulk RNA-seq and GSE168018 for scRNA-seq. Raw microbial

sequencing alignments are available from NCBI SRA under BioProject PRJNA704082. Code

used   for   differential   expression   analysis   is   available   at

https://github.com/bspeco/VAPinCOVID19.

Figure 1: Sample selection and study flowchart.
Patients were enrolled in two cohorts. Cohort 1 consisted of COVID-19 patients from the COVID
Multiphenotyping for Effective Therapies (COMET) and related Immunophenotyping Assessment
in a COVID-19 Cohort (IMPACC) studies (described in Methods). Cohort 2 consisted of critically
ill intubated control patients from a prior prospective cohort study led by our research group (18).
The "early" samples were the first available tracheal aspirate specimens after intubation. For
COVID-19 patients who developed VAP, the "late" samples were obtained a median of two days
before VAP onset. Timing of sample collection with respect to VAP versus No-VAP groups was
matched at "early" and "late" time points. Controls included eight critically ill, mechanically
ventilated patients without LRTI. All COVID-19 patients included in the primary bulk analysis were
also included in the longitudinal host expression and microbiome analyses. Abbreviations:
VAP=ventilator-associated pneumonia; TA=tracheal aspirate; QC=quality control; sc or scRNA-
seq= single cell RNA sequencing; PNA=pneumonia; CDC=United States Centers for Disease
Control and Prevention.

811
812
813
Figure 2: COVID-19 VAP is associated with a lower respiratory tract transcriptional signature of bacterial infection 2 days before VAP onset.

814
815

A) Heatmap of the top 50 differentially expressed genes by adjusted P-value between COVID-19
patients who developed VAP (yellow) versus those who did not (red) at the "late" time-point, 2
days before the onset of VAP, from bulk RNA-seq. **B)** Gene set enrichment analysis (GSEA) at
the "late" time-point based on differential gene expression analyses. GSEA results were
considered significant with an adjusted P-value <0.05. **C)** Ingenuity Pathway Analysis (IPA) of
upstream cytokines at the "late" time-point based on differential gene expression analyses. IPA
results were considered significant with a Z-score absolute value >2 and overlap P-value <0.05.
*Denotes cytokines with an overlap P-value < 0.1. All pathways and cytokines are shown in
Supplementary data files 2 and 3.

Figure 3

Figure 3: COVID-19 patients who develop VAP have attenuated immune signaling in the
lower respiratory tract two weeks before onset of secondary bacterial pneumonia.
A) Heatmap of the top 50 differentially expressed genes by adjusted P-value between COVID-19
patients who developed VAP (blue) versus those who did not (green) at the "early" time-point from
bulk RNA-seq. **B)** Gene set enrichment analysis at the "early" time-point based on differential
gene expression analyses. GSEA results were considered significant with an adjusted P-value
<0.05. **C)** Expression of GSEA pathways at the "early" time-point with respect to a baseline of
uninfected, intubated controls. Pathways were selected from the GSEA results if they had an
adjusted P-value <0.05 in at least one of the comparisons (VAP vs controls or No-VAP vs
controls). Pathways with an adjusted P-value <0.05 when compared to controls are indicated by
circles with a black outline. **D)** Ingenuity Pathway Analysis (IPA) of upstream cytokines at the
"early" time-point based on differential gene expression analyses. IPA results were considered
significant with a Z-score absolute value >2 and overlap P-value <0.05. *Denotes cytokines with
an overlap P-value <0.1. All pathways and cytokines are shown in Supplementary data files 2 and
3.

Figure 4

Figure 4: scRNA-seq demonstrates that COVID-19 VAP is associated with early impaired anti-bacterial immune signaling in lower respiratory tract monocytes, macrophages and neutrophils.

A) UMAP of single cell RNA-seq data from patients that do or do not develop VAP at the "early" time-point, annotated by cell type. **B)** Cell type proportions in single cell RNA-seq from VAP and No-VAP patients at the "early" time-point. Bars represent the median with IQR. Statistical significance was determined by Mann-Whitney tests. None of the cell types were significantly different with a p-value <0.05. The p-values for each cell type are as follows: B cells: 0.073; Neutrophils: 0.28; T/NK cells: 0.21; Secretory: 0.46; Ciliated: 0.94, and Mono/Mac: 0.81. **C)** Volcano plot displaying the differentially expressed genes between VAP and No-VAP patients in monocytes and macrophages. **D)** Ingenuity Pathway Analysis (IPA) of key canonical pathways and upstream cytokines based on differential gene expression analysis in monocytes and macrophages of patients who develop VAP versus those who do not, with adjusted p-values < 0.05. Only significant pathways (IPA Z-score of >2 or <-2 and overlap p-value <0.05) are shown. **E)** Volcano plot displaying the differentially expressed genes between VAP and No-VAP patients in neutrophils. **F)** IPA of canonical pathways and upstream cytokines based on differential gene expression analysis in neutrophils of patients who develop VAP versus those who do not, with adjusted p-values < 0.05. Only significant pathways (IPA Z-score of >2 or <-2 and overlap p-value <0.05) are shown. All pathways and cytokines are shown in Supplementary data files 5 and 6.

Figure 5

Figure 5: Temporal dynamics of the host response to VAP

A) Heatmap of the top 50 differentially expressed genes by adjusted P-value between COVID-19 patients who developed VAP at the "early" time-point (blue) versus the "late" time-point (yellow) from bulk RNA-seq. **B)** Gene set enrichment analysis (GSEA) based on differential gene expression of VAP patients at the "early" vs "late" time-point from bulk RNA-seq. GSEA results were considered significant with an adjusted P-value <0.05. **C)** Ingenuity Pathway Analysis (IPA) of upstream cytokines based on differential gene expression analyses of VAP patients at the "early" vs "late" time-point from bulk RNA-seq. IPA results were considered significant with a Z-score absolute value >2 and overlap P-value <0.05. **(D-E)** Ingenuity Pathway Analysis (IPA) of key canonical pathways based on differential gene expression analysis in monocytes and macrophages (D) or neutrophils (E) from scRNA-seq of patients who develop VAP versus those who do not, with adjusted p-values < 0.05. Only significant pathways (IPA Z-score of >2 or <-2 and overlap p-value <0.05) are shown. All pathways and cytokines are shown in Supplementary data files 2, 3, 5, and 6. **(F-I)** Longitudinal analysis of selected pathway expression in VAP (blue) versus No-VAP (green) patients from bulk RNA-seq samples taken from time of intubation to onset of VAP for all patients. Pathway Z-scores were calculated by averaging Z-scores for the top 20 leading edge genes of each pathway, determined by the results of GSEA comparing VAP versus No-VAP patients at the "early" time-point. Multiple Z-scores per patient at a given time interval were averaged so that each patient corresponds to one datapoint at each interval. Samples from day 21+ after intubation are not shown due to a lack of these later time-points in the No-VAP group. VAP onset in these patients ranged from 10-39 days post intubation. Selected pathways are innate immune system (F), neutrophil degranulation (G), cytokine signaling (H), and adaptive immune system (I). Box plots represent the median and range. Statistical significance was determined by two-way ANOVA, and interaction p-values are shown.

Figure 6

Figure 6: Lung microbiome community collapse precedes VAP in COVID-19 patients.
(A) SARS-CoV-2 viral load (reads per million sequenced, rpM) over time by days since intubation in patients who develop VAP vs those who do not. For plotting purposes, log(rpM+1) was used to avoid negative values. Lung microbiome **(B)** bacterial diversity (Shannon's Index) and **(C)** β−diversity (Bray Curtis Index, NMDS scaling) in COVID-19 patients with relation to VAP development over time by days since intubation. Box plots represent the median and range (A-C). Statistical significance was determined by two-way ANOVA. P-values <0.05 were considered significant.

Figure 7: Mechanistic hypothesis of secondary bacterial pneumonia susceptibility in patients with COVID-19.
Individual immune responses to SARS-CoV-2 infection drive a restructuring of the microbial community and increase susceptibility to VAP. Those predisposed to VAP have increased type I interferon responses and dysregulated antibacterial immune signaling characterized by impaired macrophage, neutrophil and T cell activity, decreased TLR signaling and impaired activation of key cytokines important for pathogen defense including IL-1, IL-6, IL-8, TNF, and IL-17. This state of suppressed immunity disrupts the lower respiratory tract microbiome, predisposing to outgrowth of bacterial pathogens and VAP.